InvestSource Inc.: Hall-of-Fame Jockey Jorge Velasquez Appointed To Hybred International's Board of Advisers

Jul 14, 2008 (M2 PRESSWIRE via COMTEX) -- NGSX | Quote | Chart | News | PowerRating -- Stocks in the News: Hybred International, Inc., (PINKSHEETS: HYII), Eddie Bauer, Inc. (NASDAQ: EBHI), NeurogesX, Inc. (NASDAQ: NGSX), Bioheart, Inc. (NASDAQ: BHRT)

Jul 11, 2008 -- Hybred International, Inc., (PINKSHEETS: HYII | Quote | Chart | News | PowerRating) which has a patent-pending horseshoe that prevents injuries using a built-in shock absorber that protects horses hooves, announced today that Hall of Fame jockey Jorge Velasquez has been appointed to the company's board of advisers. Velasquez is best known as the regular rider of racing's most famous runner-up, Alydar. In 1978 he rode Alydar to three dramatic second-place finishes to Affirmed in the Kentucky Derby, Preakness and Belmont. The Hall of Fame jockey rode 6,795 races in his career, including winning the Breeders' Cup Classic in 1985 atop Proud Truth as well as the 1981 Derby and Preakness aboard Pleasant Colony. Gary Kouletas, founder and president of Hybred International, said, "We are proud to have Jorge join our board of advisers and his confidence in the value of the Hybred Horseshoe. He understands how important this development is to horse racing." Velasquez said, "The Hybred Horseshoe with its built-in shock absorber for the horse, reduces the constant pounding that horses must endure on the track." Other members of the Hybred International Board of Advisors are Ian McKinlay, the leading authority on hoof lameness; Mike Wildenstein, professor at Cornell University's renowned Farrier School, who recently was inducted into the Farrier Hall of Fame.

Anaheim-based Thoro'Bred, Inc., the world's largest aluminum horseshoe manufacturer, has agreed to make the shoes. It will manufacture the aluminum part in California and ship the shoes to a plant in upstate New York, where urethane will be bonded onto it.

In addition, Thoro'Bred has agreed to market the shoe in its catalogue and marketing materials and has granted Hybred International the use of its customer and mailing lists, opening the doors to virtually every domestic tack shop, farrier and supply store in the U.S.

Jul 11, 2008 -- Eddie Bauer, Inc. (NASDAQ: EBHI | Quote | Chart | News | PowerRating) announced today an exclusive partnership with mountaineering legend Jim Whittaker, reestablishing a relationship initiated 45 years ago when Whittaker became the first American to summit Mt. Everest, the world's highest peak. Eddie Bauer outfitted the historic 1963 Everest expedition and subsequent climbs by Whittaker and other world-renowned mountaineers. In his new role with Eddie Bauer, Whittaker will consult on product development, assist with marketing campaigns, and serve as a spokesperson for the brand. "We can't think of a more natural partnership than this one with Jim, a true American pioneer whose heroic achievements have become an inspiration to us all," says Neil Fiske, President and CEO of Eddie Bauer. "His expertise, bold sense of adventure, and passion for the outdoors will help us reinvigorate the brand, and return to our roots as the original outdoor outfitter." Since 1953, Eddie Bauer has been the foremost expedition outfitter, providing cold-weather outerwear and gear for more than 40 major climbing expeditions all over the globe, including 5 first-world ascents, 4 first- American ascents, and 3 first-route ascents.

"Eddie Bauer paved the way for expedition outfitting, and made huge strides in outerwear technology," says Whittaker. "It's exciting to see the company focus on what it's best at, and I look forward to sharing my experiences to help Eddie Bauer get back to the summit, literally and figuratively."

Jul 11, 2008 -- NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site. The randomized, single-blind Phase 1 trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of 2008. Anthony DiTonno, President and CEO of NeurogesX, commented, "The initiation of this Phase 1 trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase 1 trial will provide us with important information that will help shape the design of further studies with the product candidate. We are pleased with the Company's progress with NGX-1998 advancing in the clinic and NGX-4010 under regulatory review in Europe and approaching NDA submission in the United States."

Jul 11, 2008 -- Bioheart, Inc. (NASDAQ: BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced it has secured worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S (Denmark), has 510k market clearance from the US Food and Drug Administration for marketing in the U.S. and CE mark approval for marketing in Europe and other countries that follow this mark. The Company is planning to begin immediate commercial distribution. The compact Bioheart 3370 Heart Failure Monitor engages patients through personalized daily interactions and questions, while collecting vital signs and transmitting the information directly into a database. It is uniquely available in both a wireless configuration and through hook-up to regular telephone lines. The data are regularly monitored by a remotely located medical professional, who watches for any abnormal readings that may signal a change in the patient's health status. These changes are reported back to the treating physician. "We are very excited about this tremendous opportunity to better serve the Congestive Heart Failure patient population and their physicians," said Howard J. Leonhardt, Bioheart's CEO and Chief Technology Officer. "This technology is highly synergistic to our work with MyoCell Therapy, an investigational cell therapy for the potential treatment of chronic heart damage, and marks the beginning of our ability to offer new intelligent devices that complement cell transplantation."

Market Wrap for July 11th, 2008

It was another volatile session on Wall Street as the Dow Jones Industrial Average fell more than 200 points to break below 11,000 for the first time in two years. It made its way back into positive ground, though only for a moment. Renewed pessimism sent the Dow markedly lower to finish the session with a 128 point loss. Stocks spent nearly the entire session trading with sizeable losses as investors continued to fret over Fannie Mae (FNM 10.25, -2.95) and Freddie Mac (FRE 7.75, -0.25). Only when a Reuters source indicated the two lenders would have access to the Fed's discount window did stocks rally into the green. The notion that capital would be available to the lenders if they were in dire need assuaged concern and lifted the shares; short-covering aided in the recovery. However, when the Fed would not confirm it would lend to Fannie or Freddie, stocks surrendered their gains. The concerns surrounding Fannie and Freddie overwhelmed news from General Electric (GE 27.66, +0.02), an enriched buyout bid for Anheuser-Busch (BUD 66.50, +5.29), and encouraging economic data. For the second quarter GE earned $0.54 per share matching the consensus earnings estimate. GE also announced it is divesting its consumer finance business in Japan for $5.4 billion. GE announced yesterday it is considering spinning off its consumer and industrial business. The firm is trying to focus on higher return opportunities. Belgian brewer InBev increased its bid to acquire shares of BUD to $70 per share, up from $65 per share, according to The Wall Street Journal. Shares of BUD climbed higher in response to the offer, unaffected by the turmoil surrounding the broader market. Importantly, the May trade deficit narrowed to $59.8 billion from a revised $60.5 billion in April. The real trade deficit fell to $43.6 billion from $46.7 billion in April. After trading off its highs in recent sessions, crude oil prices surged to a new record of $147.27 per barrel in early trading, only adding to the session's pessimism. It closed its session just below the $145 per barrel mark.

ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO TO: www.investsourceinc.com.

To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to www.ceo-corner.com This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation to buy or sell securities. InvestSource, Inc. has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by InvestSource, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this release have not given an opinion or approved the statements made in this release.

InvestSource, Inc. is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. InvestSource, Inc. affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. InvestSource, Inc. will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market. Please consult your broker before purchasing or selling any securities mentioned herein. InvestSource has agreed to be compensated 75,000 unrestricted shares of HYII for services rendered. To view full disclaimers, please go to http://investsourceinc.com/php/disclaimer.php (disclaimers).

CONTACT: InvestSource, Inc WWW: http://www.investsourceinc.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index